Cathelicidin LL-37: A Multitask Antimicrobial Peptide

被引:0
|
作者
Robert Bucki
Katarzyna Leszczyńska
Andrzej Namiot
Wojciech Sokołowski
机构
[1] University of Pennsylvania,Institute for Medicine and Engineering
[2] Medical University of Bialystok,Department of Diagnostic Microbiology
[3] Medical University of Bialystok,Department of Anatomy
来源
Archivum Immunologiae et Therapiae Experimentalis | 2010年 / 58卷
关键词
Antibacterial agents; Bacteria; Infection; hCAP-18;
D O I
暂无
中图分类号
学科分类号
摘要
The antimicrobial peptide LL-37 is the only known member of the cathelicidin family of peptides expressed in humans. LL-37 is a multifunctional host defense molecule essential for normal immune responses to infection and tissue injury. LL-37 peptide is a potent killer of different microorganisms with the ability to prevent immunostimulatory effects of bacterial wall molecules such as lipopolysaccharide and can therefore protect against lethal endotoxemia. Additional reported activities of LL-37 include chemoattractant function, inhibition of neutrophil apoptosis, and stimulation of angiogenesis, tissue regeneration, and cytokine release (e.g. IL-8). Cellular production of LL-37 is affected by multiple factors, including bacterial products, host cytokines, availability of oxygen, and sun exposure through the activation of CAP-18 gene expression by vitamin D3. At infection sites, the function of LL-37 can be inhibited by charge-driven interactions with DNA and F-actin released from dead neutrophils and other cells lysed as the result of inflammation. A better understanding of LL-37’s biological properties is necessary for its possible therapeutic application for immunomodulatory purposes as well as in treating bacterial infection.
引用
收藏
页码:15 / 25
页数:10
相关论文
共 50 条
  • [1] Cathelicidin LL-37: A Multitask Antimicrobial Peptide
    Bucki, Robert
    Leszczynska, Katarzyna
    Namiot, Andrzej
    Sokolowski, Wojciech
    ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2010, 58 (01) : 15 - 25
  • [2] LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity
    Adam Fabisiak
    Natalia Murawska
    Jakub Fichna
    Pharmacological Reports, 2016, 68 : 802 - 808
  • [3] Cathelicidin LL-37: An Antimicrobial Peptide with a Role in Inflammatory Skin Disease
    Reinholz, Markus
    Ruzicka, Thomas
    Schauber, Juergen
    ANNALS OF DERMATOLOGY, 2012, 24 (02) : 126 - 135
  • [4] LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity
    Fabisiak, Adam
    Murawska, Natalia
    Fichna, Jakub
    PHARMACOLOGICAL REPORTS, 2016, 68 (04) : 802 - 808
  • [5] ANTIMICROBIAL PEPTIDE CATHELICIDIN (LL-37) CONCENTRATION IN ACTIVE PULMONARY TUBERCULOSIS PATIENTS
    Sovira, N.
    Sutoyo, D. K.
    Burhan, E.
    Dillon, D. H.
    RESPIROLOGY, 2012, 17 : 133 - 133
  • [6] The human cathelicidin antimicrobial peptide LL-37 and mimics are potential anticancer drugs
    Kuroda, Kengo
    Okumura, Kazuhiko
    Isogai, Hiroshi
    Isogai, Emiko
    FRONTIERS IN ONCOLOGY, 2015, 5
  • [7] Cathelicidin LL-37 (an antimicrobial peptide)-induced colistin dependence in Acinetobacter baumannii
    Lee, Ji-Young
    Hong, Yoon-Kyoung
    Ko, Kwan Soo
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2020, 96 (04)
  • [8] The impact of cathelicidin, the human antimicrobial peptide LL-37 in urinary tract infections
    Babikir, Ibrahim H.
    Abugroun, Elsir A.
    Bilal, Naser Eldin
    Alghasham, Abdullah Ali
    Abdalla, Elmuataz Elmansi
    Adam, Ishag
    BMC INFECTIOUS DISEASES, 2018, 18
  • [9] The impact of cathelicidin, the human antimicrobial peptide LL-37 in urinary tract infections
    Ibrahim H. Babikir
    Elsir A. Abugroun
    Naser Eldin Bilal
    Abdullah Ali Alghasham
    Elmuataz Elmansi Abdalla
    Ishag Adam
    BMC Infectious Diseases, 18
  • [10] Antimicrobial human cathelicidin, LL-37, in breast milk
    Yoshio, H.
    Yamada, M.
    Yoshida, M.
    Takeuchi, A.
    Endo, S.
    Kageyama, M.
    Nakamura, M.
    Yamauchi, Y.
    Agerberth, B.
    ACTA PAEDIATRICA, 2007, 96 : 220 - 221